Related Experiment Video

Updated: Aug 19, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

EGF-dependent growth inhibition in MDA-468 human breast cancer cells is characterized by late G1 arrest and altered

K A Prasad1, J G Church

  • 1Terry Fox Cancer Research Labs, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada.

Experimental Cell Research
|July 1, 1991
PubMed

Insights

Epidermal Growth Factor (EGF) paradoxically inhibits growth in MDA-468 breast cancer cells. This study reveals EGF causes a reversible G1/S phase cell cycle block by downregulating p53 and histone 3.2.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • The MDA-468 human breast cancer cell line exhibits paradoxical growth inhibition upon exposure to epidermal growth factor (EGF).
  • Understanding the cellular mechanisms behind EGF-induced growth inhibition is crucial for breast cancer research.

Purpose of the Study:

  • To elucidate the cellular mechanisms underlying EGF-induced growth inhibition in MDA-468 cells.
  • To identify specific cell cycle events and gene expressions affected by EGF treatment.

Main Methods:

  • Flow cytometry was used to analyze cell cycle distribution (G1, S, G2/M phases) after EGF treatment.
  • DNA synthesis was quantified using [3H]thymidine incorporation.
  • Northern blot analysis assessed the expression of cell cycle-dependent genes (c-myc, PCNA, thymidine kinase, p53, histone 3.2).

Main Results:

  • EGF treatment led to an accumulation of cells in the G1 phase and a decrease in S and G2/M phases.
  • DNA synthesis was significantly reduced by approximately 35% after 48 hours of EGF exposure, with recovery upon EGF removal.
  • EGF down-regulated the expression of p53 and histone 3.2, genes associated with the G1/S boundary and S phase, respectively, while early and late G1 markers remained unaffected.

Conclusions:

  • EGF-induced growth inhibition in MDA-468 cells is characterized by a reversible cell cycle arrest at the G1/S boundary.
  • The downregulation of p53 and histone 3.2 expression appears to be a key mechanism mediating this EGF-induced G1/S block.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...